C([N:8]1[CH2:13][CH2:12][CH:11]([N:14]2[C:18]3=[N:19][C:20]([Cl:31])=[N:21][C:22]([N:23]4[CH2:29][CH:28]5[O:30][CH:25]([CH2:26][CH2:27]5)[CH2:24]4)=[C:17]3[CH:16]=[N:15]2)[CH2:10][CH2:9]1)C1C=CC=CC=1.ClC(OC(Cl)C)=O.C([O-])([O-])=O.[K+].[K+]>ClCCCl>[Cl:31][C:20]1[N:19]=[C:18]2[N:14]([CH:11]3[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]3)[N:15]=[CH:16][C:17]2=[C:22]([N:23]2[CH2:24][CH:25]3[O:30][CH:28]([CH2:27][CH2:26]3)[CH2:29]2)[N:21]=1To 1-(1-benzyl-piperidin-4-yl)-6-chloro-4-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidine (0.24 mmol) in 1,2-dichloroethane (2 mL) is added 1.9 mmol alpha-chloroethyl chloroformate (ACE-Cl) along with a small amount of K2CO3. The mixture is stirred for 5.5 h at RT. The reaction is quenched by addition of MeOH and the mixture is filtered and concentrated to dryness. The mixture is dissolved in MeOH and briefly heated to reflux. The title compound is obtained in quantitative yield by evaporation of MeOH. This material is used without further purification in the next step (reductive amination or acylation following the procedures disclosed previously, Scheme 30).
Loading…